<DOC>
	<DOC>NCT02645981</DOC>
	<brief_summary>Donafenib versus sorafenib for advanced hepatocellular cancer.</brief_summary>
	<brief_title>Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients wiht advanced hepatocellular carcinoma (HCC).The study is a randomised,controlled,multicentre study.The controlled drug is sorafenib(Nexavar).The primary endpoint is overall survival.</detailed_description>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Above 18 years old; Patients with measurable, histologically or clinical proven, inoperable HCC; Patients wtih measurable lesion and proved by independent radiology committee(IRC); ChildPugh (CP) score of 7 or less； Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less; Patients had not received prior systemic treatments for HCC; Life expectancy at least 3 months; Adequate hepatic and renal function; Adequate hematologic function (platelet count,≥75×109per liter;hemoglobin ≥9.0g per deciliter;neutrophil≥1.5×109per liter,); Prothrombin time international normal. Patients received operate in 3 months; Patients received transcatheter arterial chemoembolization（TACE） in 4 weeks; Patients had received systemic therapy; Patients had prior treatment with sorafenib; Central nervous system(CNS) involvement; Severe or milddegree ascitic fluid; Main portal vein tumor thrombus; Inferior venae cava tumor thrombus.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Donafeinb</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Overall Survival</keyword>
</DOC>